Waller C F, Fetscher S, Lange W
Department of Internal Medicine 1, Hematology/Oncology, Albert-Ludwigs-University, Freiburg Medical Center, Freiburg, Germany.
Ann Hematol. 1999 Aug;78(8):341-54. doi: 10.1007/s002770050527.
Treatment-related (Tr) AML and MDS after chemotherapy, radiotherapy, or the combination of both have been well characterized. However, tr-CML seems to differ from these better-known entities in frequency, clinical course, and prognosis. Tr-CML cannot be distinguished from de novo CML cytogenetically, and, in contrast to tr-AML and tr-MDS, typical chromosomal aberrations related to tr-CML have not been described. Treatment-related CML is a late effect of cytotoxic or immunosuppressive therapy which might be increasingly recognized due to a higher number of patients treated with intensive therapy regimens. We review here the available data on incidence of tr-CML as well as the affected individual's characteristics with regard to different treatment options in malignant and nonmalignant diseases.
化疗、放疗或两者联合治疗后发生的治疗相关（Tr）急性髓系白血病（AML）和骨髓增生异常综合征（MDS）已得到充分描述。然而，治疗相关慢性髓系白血病（tr-CML）在发病率、临床病程和预后方面似乎与这些更为人熟知的疾病有所不同。tr-CML在细胞遗传学上无法与原发性CML区分开来，并且与tr-AML和tr-MDS不同，尚未描述与tr-CML相关的典型染色体畸变。治疗相关CML是细胞毒性或免疫抑制治疗的晚期效应，由于接受强化治疗方案的患者数量增加，可能会越来越多地被认识到。我们在此回顾关于tr-CML发病率以及在恶性和非恶性疾病中不同治疗选择下受影响个体特征的现有数据。
